Ashraf S Ibrahim, PhD

home / authors / ashraf-s-ibrahim-phd

Senior Investigator at The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.

Articles

Humanizing Monoclonal Antibodies for Mucormycosis Treatment

Humanizing Monoclonal Antibodies for Mucormycosis Treatment

Sophia Abene;Ashraf S Ibrahim, PhD
April 1st 2025

Ashraf S Ibrahim, PhD, details over 20 years of research on a spore coating protein and the development of VX-01 to block fungal tissue invasion.

Read More

VX-01 Monoclonal Antibody Targets Mucormycosis by Blocking Angioinvasion

VX-01 Monoclonal Antibody Targets Mucormycosis by Blocking Angioinvasion

Sophia Abene;Ashraf S Ibrahim, PhD
March 31st 2025

Ashraf S Ibrahim, PhD, discusses how VX-01 prevents fungal invasion of blood vessels and enhances immune response in immunocompromised patients.

Read More

Latest Updated Articles

Concerns Over Mosquito-Borne Illness Causes Massachusetts Town to Create Curfew for Parks, Spraying in Counties
Published: August 27th 2024 | Updated: August 28th 2024
Concerns Over Mosquito-Borne Illness Causes Massachusetts Town to Create Curfew for Parks, Spraying in Counties
With the Rise of COVID-19 Vaccines, a Greater Public Mistrust of Immunizations Has Taken Hold
Published: March 25th 2025 | Updated: April 2nd 2025
With the Rise of COVID-19 Vaccines, a Greater Public Mistrust of Immunizations Has Taken Hold
FDA Approves Gepotidacin (Blujepa) for Uncomplicated Urinary Tract Infections
Published: March 25th 2025 | Updated: April 2nd 2025
FDA Approves Gepotidacin (Blujepa) for Uncomplicated Urinary Tract Infections
How a Prodrug Approach May Aid In Antimalarial Development
Published: March 21st 2025 | Updated: April 2nd 2025
How a Prodrug Approach May Aid In Antimalarial Development
Large Hospital System Experiences Significant Increases in Candida auris
Published: March 21st 2025 | Updated: April 2nd 2025
Large Hospital System Experiences Significant Increases in Candida auris
Immunocore Reports Some PWH Achieve Viral Control and Dose-Dependent Active HIV Reservoir Reduction in IMC-M113V Trial
Published: March 17th 2025 | Updated: April 2nd 2025
Immunocore Reports Some PWH Achieve Viral Control and Dose-Dependent Active HIV Reservoir Reduction in IMC-M113V Trial
© 2025 MJH Life Sciences

All rights reserved.